13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D Filed 2026-06-24 Event 2026-06-16 SEC 0000908834-26-000312 →

FARALLON CAPITAL MANAGEMENT, L.L.C. Centessa Pharmaceuticals plc

Stake: 6.10% Shares: 9,370,093 CUSIP: 152309100 Class: Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares")

Item 4 — Purpose of Transaction

The disclosure set forth in Items 5 and 6 below is hereby incorporated by reference in this Item 4. The Reporting Persons believe the securities of the Issuer represent an attractive investment opportunity. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending upon various factors, including, without limitation, the Issuer's financial position and strategic direction, overall market conditions, general economic and industry conditions, other investment opportunities available to the Reporting Persons, the liquidity requirements of the Reporting Persons, price levels of the Ordinary Shares and the ADSs, and any contractual provisions to which the Reporting Persons may then be subject, the Reporting Persons in the future may take actions with respect to their investment position in the Issuer as they deem appropriate, including, without limitation, purchasing additional Ordinary Shares or ADSs, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; selling, exchanging, converting, pledging or financing some or all of the securities reported herein, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; engaging in hedging or similar transactions with respect to Ordinary Shares or ADSs, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; and taking any other action to maximize the value of the Reporting Persons' investment position in the Issuer. Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.

Cross-References

Insider Activity (last 365d)
1 transaction
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
7 filings by this filer
6 other filings in the data moat
Short Interest
Not in latest FINRA snapshot

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-05-01 Accardi Mario Alberto director, officer F 604 $39.42 $24K

Other 13D/G Filings on Centessa Pharmaceuticals plc

FiledFormFilerStakeShares
2026-06-26 SCHEDULE 13D/A FARALLON CAPITAL MANAGEMENT, L.L.C. 0 view →

Other Filings by FARALLON CAPITAL MANAGEMENT, L.L.C.

FiledFormIssuerStakeShares
2026-06-26 SCHEDULE 13D/A Centessa Pharmaceuticals plc 0 view →
2023-03-15 SC Atento S.A. view →
2021-11-15 SC Playa Hotels & Resorts N.V. view →
2021-05-21 SC Playa Hotels & Resorts N.V. view →
2021-01-15 SC Playa Hotels & Resorts N.V. view →
2020-11-24 SC Playa Hotels & Resorts N.V. view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →